Adjuvant Alectinib in ALK-Rearranged NSCLC — Here and Now

This editorial discusses the ALINA phase 3 trial, which evaluated adjuvant alectinib therapy in patients with resected ALK rearranged non small cell lung cancer (NSCLC). The trial demonstrated significantly prolonged disease free survival compared to platinum based chemotherapy, with notable benefits in CNS disease recurrence. The authors explore implications for treatment paradigms, duration of therapy, and the integration of molecular profiling in early-stage NSCLC.

This editorial discusses the ALINA phase 3 trial, which evaluated adjuvant alectinib therapy in patients with resected ALK rearranged non small cell lung cancer (NSCLC). The trial demonstrated significantly prolonged disease free survival compared to platinum based chemotherapy, with notable benefits in CNS disease recurrence. The authors explore implications for treatment paradigms, duration of therapy, and the integration of molecular profiling in early-stage NSCLC.